Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

by NASDAQ Market News October 23, 2019

NASDAQ Market News
Click here to email author

New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor

BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program

Ads